219 related articles for article (PubMed ID: 36458710)
1. [Evaluation of Serum Pentraxin-3 and suPAR Levels as Acute Phase Reactants in Patients with COVID-19].
Akbayırlı U; Kaya S; Aksoy Gökmen A
Mikrobiyol Bul; 2022 Oct; 56(4):631-644. PubMed ID: 36458710
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
Kerget B; Kerget F; Aksakal A; Aşkın S; Uçar EY; Sağlam L
J Med Virol; 2021 Sep; 93(9):5568-5573. PubMed ID: 34019703
[TBL] [Abstract][Full Text] [Related]
3. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
[TBL] [Abstract][Full Text] [Related]
4. [Ventilator bundle treatment of acute respiratory distress syndrome and its correlation with biomarkers of inflammation].
Yang J; Dong C; Li J; Zhang H; Zhang H; Song R; Yang Z; Feng F; Qi Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Aug; 26(8):544-8. PubMed ID: 25124901
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.
Padelli M; Gueye P; Guilloux D; Banydeen R; Campana V; Cabie A; Neviere R
Biomark Med; 2022 Feb; 16(3):169-177. PubMed ID: 35081737
[TBL] [Abstract][Full Text] [Related]
8. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
Vasbinder A; Padalia K; Pizzo I; Machado K; Catalan T; Presswalla F; Anderson E; Ismail A; Hutten C; Huang Y; Blakely P; Azam TU; Berlin H; Feroze R; Launius C; Meloche C; Michaud E; O'Hayer P; Pan M; Shadid HR; Rasmussen LJH; Roberts DA; Zhao L; Banerjee M; Murthy V; Loosen SH; Chalkias A; Tacke F; Reiser J; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Pop-Busui R; Hayek SS;
J Med Virol; 2024 Jan; 96(1):e29389. PubMed ID: 38235904
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Reisinger AC; Niedrist T; Posch F; Hatzl S; Hackl G; Prattes J; Schilcher G; Meißl AM; Raggam RB; Herrmann M; Eller P
Sci Rep; 2021 Sep; 11(1):17476. PubMed ID: 34471146
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
Stauning MA; Altintas I; Kallemose T; Eugen-Olsen J; Lindstrøm MB; Rasmussen LJH; Gamst-Jensen H; Nehlin JO; Andersen O; Tingleff J
J Emerg Med; 2021 Sep; 61(3):298-313. PubMed ID: 34092446
[TBL] [Abstract][Full Text] [Related]
11. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
[TBL] [Abstract][Full Text] [Related]
12. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
13. suPAR as a marker of infection in acute kidney injury - a prospective observational study.
Hall A; Crichton S; Varrier M; Bear DE; Ostermann M
BMC Nephrol; 2018 Aug; 19(1):191. PubMed ID: 30071826
[TBL] [Abstract][Full Text] [Related]
14. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study.
Arnold DT; Attwood M; Barratt S; Morley A; Elvers KT; McKernon J; Donald C; Oates A; Noel A; MacGowan A; Maskell NA; Hamilton FW
Emerg Med J; 2021 Jul; 38(7):543-548. PubMed ID: 34021028
[TBL] [Abstract][Full Text] [Related]
15. Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives.
Assandri R; Accordino S; Canetta C; Buscarini E; Scartabellati A; Tolassi C; Serana F
Biochem Med (Zagreb); 2022 Jun; 32(2):020901. PubMed ID: 35464745
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS).
Şirinoğlu M; Soysal A; Karaaslan A; Kepenekli Kadayifci E; Yalındağ-Öztürk N; Cinel İ; Yaman A; Haklar G; Şirikci Ö; Turan S; Altınkanat Gelmez G; Söyletir G; Bakır M
J Infect Chemother; 2017 Jan; 23(1):17-22. PubMed ID: 27771157
[TBL] [Abstract][Full Text] [Related]
17. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.
El-Mekkawy MS; Saleh NY; Sonbol AA
Indian J Pediatr; 2016 Jul; 83(7):661-9. PubMed ID: 26960717
[TBL] [Abstract][Full Text] [Related]
18. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
Sarif J; Raychaudhuri D; D'Rozario R; Bandopadhyay P; Singh P; Mehta P; Hoque MA; Sinha BP; Kushwaha M; Sahni S; Devi P; Chattopadhyay P; Paul SR; Ray Y; Chaudhuri K; Banerjee S; Majumdar D; Saha B; Sarkar BS; Bhattacharya P; Chatterjee S; Paul S; Ghosh P; Pandey R; Sengupta S; Ganguly D
Front Immunol; 2021; 12():738093. PubMed ID: 34777349
[TBL] [Abstract][Full Text] [Related]
19. Ability of combined soluble urokinase plasminogen activator receptor to predict preventable emergency attendance in older patients in Japan: a prospective pilot study.
Mitsunaga T; Ohtaki Y; Yajima W; Sugiura K; Seki Y; Mashiko K; Uzura M; Takeda S
PeerJ; 2022; 10():e14322. PubMed ID: 36353607
[TBL] [Abstract][Full Text] [Related]
20. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.
Suberviola B; Castellanos-Ortega A; Ruiz Ruiz A; Lopez-Hoyos M; Santibañez M
Intensive Care Med; 2013 Nov; 39(11):1945-52. PubMed ID: 23949703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
